Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab) (STELARA CD PMS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03942120|
Recruitment Status : Recruiting
First Posted : May 8, 2019
Last Update Posted : November 1, 2019
|Condition or disease||Intervention/treatment|
|Crohn Disease||Drug: Ustekinumab|
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||Post-Marketing Surveillance for Crohn's Disease Patients Treated With STELARA|
|Actual Study Start Date :||April 8, 2019|
|Estimated Primary Completion Date :||April 5, 2022|
|Estimated Study Completion Date :||April 5, 2022|
Participants with Crohn's Disease
Participants that are diagnosed with Crohn's disease will be observed in this study who are being treated with ustekinumab under real world clinical practice. Only data available per clinical practice will be collected within this study.
Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.
Other Name: Stelara
- Number of Participants with Adverse Events [ Time Frame: Approximately up to 3 years ]An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
- Change from Baseline in Crohn's Disease Activity Index (CDAI) Score [ Time Frame: Baseline up to 3 years ]CDAI is a scoring system to assess the symptoms of participants with Crohn's disease (CD). It consists of 8 different CD-related factors that are summed after adjustment with a weighting factor. These 8 variables are: extraintestinal manifestations, abdominal mass, weight, hematocrit, use of antidiarrheal drug(s) and/or opiates, total number of liquid stools, abdominal pain/cramping, and general well-being. CDAI total score ranges from 0 to 900 and a decrease over time indicates improvement in disease activity.
- Change from Baseline in C-reactive Protein (CRP) Concentration [ Time Frame: Baseline up to 3 years ]Change from baseline in CRP concentration will be assessed.
- Change from Baseline in Harvey-Bradshaw Index (HBI) Score [ Time Frame: Baseline up to 3 years ]HBI is a shorter and simpler alternative version of CDAI which consists of five parameters that allow physicians to quickly categorize the severity of Crohn's disease and detect remission. The 5 parameters are: general well-being (0-4, where higher score means lower well-being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day (score 1 per movement), abdominal mass (0=none, 1=dubious, 2=definite, 3=definite and tender), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools per day and number of complications, where higher scores indicate more severe disease and, score is presented as: less than (<)5 (remission), 5-7 (mild disease), 8-16 (moderate disease), and greater than (>)16 (severe disease).
- Change from Baseline in Fecal Calprotectin Level [ Time Frame: Baseline up to 3 years ]Change from baseline in fecal calprotectin levels will be assessed. Elevated calprotectin level in the stool indicates that inflammation is present in the intestine and the degree of elevation is associated with the severity of the inflammation.
- Change from Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) [ Time Frame: Baseline up to 3 years ]SES-CD is a simplified endoscopic scoring system to evaluate Crohn's disease activity developed as an alternative to Crohn's disease endoscopic index of severity (CDEIS). It assesses the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence stenosis. Each endoscopic component is scored from 0 to 3 for each segment, and a total score is derived from the sum of all the component scores (range, 0 [remission] to 60 [the most severe endoscopic activity]).
- Change from Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Score [ Time Frame: Baseline up to 3 years ]SIBDQ is a simple, validated 10-item self-reported questionnaire for participants with inflammatory bowel disease to evaluate participant-reported outcomes in 4 domains- digestive symptoms (3 items), systemic symptoms (2 items), emotional disturbance (3 items), and social function (2 items). Participants rate each item on a 7-point Likert scale (1=all of the time; 2=most of the time; 3=a good bit of the time; 4=some of the time; 5=a little bit of the time; 6=hardly any of the time; 7=none of the time). Total score is calculated by adding the scores from each domain; the total score ranges from 10 to 70, where minimum score =10 (poor quality of life) and maximum score =70 (good quality of life).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03942120
|Contact: Study Contact||844-434-4210||JNJ.CT@sylogent.com|
|Korea, Republic of|
|Inje University Haeundae Paik Hospital||Recruiting|
|Busan, Korea, Republic of, 48108|
|Kosin University Gospel Hospital||Recruiting|
|Busan, Korea, Republic of, 48108|
|Kyungpook National University Hospital||Recruiting|
|Daegu, Korea, Republic of, 41944|
|Yeungnam University Medical Center||Recruiting|
|Daegu, Korea, Republic of, 42415|
|Seoul National University Hospital||Recruiting|
|Seoul, Korea, Republic of, 03080|
|Kangbuk Samsung Hospital||Recruiting|
|Seoul, Korea, Republic of, 03181|
|Asan Medical Center||Recruiting|
|Seoul, Korea, Republic of, 05505|
|Samsung Medical Center||Recruiting|
|Seoul, Korea, Republic of, 06351|
|Chung-Ang University Hospital||Recruiting|
|Seoul, Korea, Republic of, 06973|
|KyungHee University Hospital||Recruiting|
|Seoul, Korea, Republic of, 102-1703|
|Study Director:||Janssen Korea, Ltd., Korea Clinical Trial||Janssen Korea, Ltd., Korea|